NCT04561245View on ClinicalTrials.gov

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions

ObesityNonalcoholic Steatohepatitis

Interventions

DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Trial Locations (1)

Unknown

Nucleus Networks, Herston

Sponsors

Lead Sponsor

Altimmune, Inc.

All Listed Sponsors

lead

Altimmune, Inc.

INDUSTRY